Drug class
TACI-Fc fusion protein; dual B-lymphocyte stimulator (BLyS/BAFF) and APRIL inhibitor biologic
Mechanism of action
A soluble fusion protein comprising the extracellular domain of TACI linked to an Fc region. It binds and neutralises BLyS (BAFF) and APRIL, reducing survival and activation signals for B cells and antibody-producing plasma cells.
General use cases
- Reduction of proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk for disease progression under the US FDA accelerated approval for atacicept-vymj (Trutakna, initial approval 2026). Long-term effect on kidney-function decline was not established in the accelerated-approval label; consult current product information.
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
